More than 40% of patients with multiple sclerosis have used cannabis or cannabinoid products in the last year, according to a study by researchers at the University of Michigan. The study, “Cannabinoid use among Americans with MS: Current trends and gaps in knowledge,” was published recently in Multiple Sclerosis Journal – Experimental, Translational and Clinical.
To conduct the research, investigators with the University of Michigan collected data from a nationwide sampling of more than 1,000 patients with multiple sclerosis. The study revealed that 42% of respondents reported using cannabis or cannabinoid-based therapies such as cannabidiol (CBD) in the prior year, a rate of use that is nearly twice that of the national average, according to the National Organization for the Reform of Marijuana Laws (NORML).
“These national survey data highlight the rising prevalence of cannabinoid use in Americans with MS, and, among users, an abiding perception of benefit for multiple chronic symptoms,” the researchers wrote.
Among the survey respondents who used cannabis or cannabinoid products, 90% said that their cannabis use was medicinal. The researchers noted that many patients with MS experience chronic symptoms that have an insufficient number of quality treatment options. More than half of all patients experience